Skip to content
Companies

Aptamino

Oral delivery of antibody drugs via protein design

Raised to date

$8M

of $8M offered across 1 Form D filing

Investors
7
Last filed
Apr 6, 2026

About

Aptamino is an early-stage biotechnology company working on oral delivery of antibody therapeutics using computational protein design. It was co-founded by CEO Julie Zhang and Isaac Lutz, who previously worked together in the George Church lab at Harvard Medical School; Lutz did his bioengineering PhD in the Baker Lab, applying reinforcement learning and generative AI to protein design. The company is operating in stealth from Cambridge, Massachusetts, with backing that includes The Engine.

Applies computational and generative protein design — the founders' background in machine-learning-driven protein engineering — to the delivery problem, aiming to make antibodies administrable orally rather than by injection or infusion.

Funding

  • EquityFiled Apr 6, 2026Form D
    $8M/ $8M

Product

Oral antibody delivery platform

Biologics drug delivery

A protein-design-based approach intended to let antibody therapeutics survive oral administration and reach systemic circulation, in place of injection or infusion. The program is pre-launch and no product name or pipeline detail has been disclosed publicly.

  • Computational protein design applied to antibody engineering
  • Oral route of administration for biologics

Built for

Patients on antibody therapeutics, reached via pharmaceutical developers and partners — no commercial product yet

People on file